Understanding the Pharmacogenomics of Anti-depressant Response: Insights from Pharmacy, Laboratory Science, Nursing and Psychology
Main Article Content
Keywords
Pharmacogenomics, Anti-depressant, Response, Pharmacy, Laboratory, Nursing and Psychology
Abstract
Drug response and side effect development have been shown to vary significantly amongst individuals receiving pharmacotherapy for neuropsychiatric diseases including depression. As a fundamental component of personalized medicine, pharmacogenetics seeks to maximize treatment based on each patient's unique genetic profile by focusing on genetic variants implicated in pharmacokinetic or pharmacodynamic processes. Pharmacodynamic variability is the outcome of an active drug's fluctuating interactions with its target molecules, while pharmacokinetic variability is the consequence of changes in a drug's absorption, distribution, metabolism, and elimination.
References
Biernacka, J. M., Sangkuhl, K., Jenkins, G., Whaley, R. M., Barman, P., Batzler, A., ... & Weinshilboum, R. (2015). The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Translational psychiatry, 5(4), e553-e553.
Brunoni, A. R., Carracedo, A., Amigo, O. M., Pellicer, A. L., Talib, L., Carvalho, A. F., ... & Cappi, C. (2019). Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial. Brazilian Journal of Psychiatry, 42, 128-135.
Cacabelos, R., & Torrellas, C. (2015). Pharmacogenomics of antidepressants. J. Psychiatr. Depress Anxiety, 1(001), 1-42.
Cascorbi, I., & Schwab, M. (2016). Epigenetics in drug response. Clinical Pharmacology & Therapeutics, 99(5), 468-470.
Fabbri, C., & Serretti, A. (2016). Pharmacogenetics of the efficacy and side effects of antidepressant drugs. Genetic influences on response to drug treatment for major psychiatric disorders, 39-54.
FDA. The FDA warns against the use of many genetic tests with unapproved claims to predict patient response to specific medications: FDA Safety Communication. Available at: https://www.fda.gov/medical-devices/safety-communications/fda-warns-against-use-many-genetic-tests-unapproved-claims-predict-patient-response-specific 2019
He, Q., Shen, Z., Ren, L., Wang, X., Qian, M., Zhu, J., & Shen, X. (2020). The association of catechol-O-methyltransferase (COMT) rs4680 polymorphisms and generalized anxiety disorder in the Chinese Han population. International Journal of Clinical and Experimental Pathology, 13(7), 1712.
Helton, S. G., & Lohoff, F. W. (2015). Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders. Pharmacogenomics, 16(5), 541-553.
Hicks, J. K., Bishop, J. R., Sangkuhl, K., Müller, D. J., Ji, Y., Leckband, S. G., ... & Gaedigk, A. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clinical Pharmacology & Therapeutics, 98(2), 127-134.
Jones, D. N., & Raghanti, M. A. (2021). The role of monoamine oxidase enzymes in the pathophysiology of neurological disorders. Journal of Chemical Neuroanatomy, 114, 101957.
Kang, H. J., Kim, K. T., Yoo, K. H., Park, Y., Kim, J. W., Kim, S. W., ... & Kim, J. M. (2020). Genetic markers for later remission in response to early improvement of antidepressants. International Journal of Molecular Sciences, 21(14), 4884.
Kuhn, D. M., & Hasegawa, H. (2020). Tryptophan hydroxylase and serotonin synthesis regulation. In Handbook of Behavioral Neuroscience (Vol. 31, pp. 239-256). Elsevier.
Kulikova, E. A., & Kulikov, A. V. (2019). Tryptophan hydroxylase 2 as a therapeutic target for psychiatric disorders: Focus on animal models. Expert Opinion on Therapeutic Targets, 23(8), 655-667.
Lauschke, V. M., Zhou, Y., & Ingelman-Sundberg, M. (2019). Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. Pharmacology & therapeutics, 197, 122-152.
Lin, E., & Lane, H. Y. (2015). Genome-wide association studies in pharmacogenomics of antidepressants. Pharmacogenomics, 16(5), 555-566.
Park, C., Rosenblat, J. D., Brietzke, E., Pan, Z., Lee, Y., Cao, B., ... & McIntyre, R. S. (2019). Stress, epigenetics and depression: a systematic review. Neuroscience & Biobehavioral Reviews, 102, 139-152.
Pigott, H. E. (2015). The STAR* D trial: It is time to reexamine the clinical beliefs that guide the treatment of major depression. The Canadian Journal of Psychiatry, 60(1), 9-13.
Pinna, M., Manchia, M., Pisanu, C., Pinna, F., Paribello, P., Carta, A., ... & Carpiniello, B. (2021). Protocol for a pharmacogenetic study of antidepressants: characterization of drug-metabolizing profiles of cytochromes CYP2D6 and CYP2C19 in a Sardinian population of patients with major depressive disorder. Psychiatric Genetics, 31(5), 186-193.
Probst-Schendzielorz, K., Scholl, C., Efimkina, O., Ersfeld, E., Viviani, R., Serretti, A., ... & Stingl, J. (2015). CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study. Pharmacogenomics, 16(7), 689-701.
RASHMI, S., SANGILIMUTHU, A. Y., & KUMAR, V. (2020). An evaluation of serotonergic genes polymorphism in the antidepressant response of major depressive disorder patients treated with escitalopram and venlafaxine. International Journal of Pharmaceutical Research (09752366).
Samardzic, J., Svob Strac, D., & van den Anker, J. N. (2017). The benefit and future of pharmacogenetics. Total Intravenous Anesthesia and Target Controlled Infusions: A Comprehensive Global Anthology, 697-711.
Shalimova, A., Babasieva, V., Chubarev, V. N., Tarasov, V. V., Schiöth, H. B., & Mwinyi, J. (2021). Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics. Pharmacogenomics, (0).
Shetty, P. (2019). Pharmacogenomics and its future implications in treatment-resistant depression. Ind. J. Priv. Psychiatry, 13, 71-76.
Singh, D. B. (2020). The impact of pharmacogenomics in personalized medicine. Current Applications of Pharmaceutical Biotechnology, 369-394.
Srivastava, K., Ochuba, O., Sandhu, J. K., Alkayyali, T., Ruo, S. W., Waqar, A., ... & Poudel, S. (2021). Effect of catechol-O-methyltransferase genotype polymorphism on neurological and psychiatric disorders: progressing towards personalized medicine. Cureus, 13(9).
Tao, S., Chattun, M. R., Yan, R., Geng, J., Zhu, R., Shao, J., ... & Yao, Z. (2018). TPH-2 gene polymorphism in major depressive disorder patients with early-wakening symptom. Frontiers in neuroscience, 12, 423425.
Tuscher, J. J., & Day, J. J. (2019). Multigenerational epigenetic inheritance: One step forward, two generations back. Neurobiology of Disease, 132, 104591.
Van Schaik, R. H., Müller, D. J., Serretti, A., & Ingelman-Sundberg, M. (2020). Pharmacogenetics in psychiatry: an update on clinical usability. Frontiers in Pharmacology, 11, 575540.
Van Westrhenen, R., Aitchison, K. J., Ingelman-Sundberg, M., & Jukić, M. M. (2020). Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going?. Frontiers in Psychiatry, 11, 479382.
Willner, P., Bergman, J., & Vanderschuren, L. (2019). The behavioural pharmacology of stress-related disorders. Behavioural Pharmacology, 30(2 and 3), 101-103.
Wyska, E. (2019). Pharmacokinetic considerations for current state-of-the-art antidepressants. Expert opinion on drug metabolism & toxicology, 15(10), 831-847.
Xin, J., Yuan, M., Peng, Y., & Wang, J. (2020). Analysis of the deleterious single-nucleotide polymorphisms associated with antidepressant efficacy in major depressive disorder. Frontiers in Psychiatry, 11, 151.
Yeung, A. W. K., Georgieva, M. G., Atanasov, A. G., & Tzvetkov, N. T. (2019). Monoamine oxidases (MAOs) as privileged molecular targets in neuroscience: research literature analysis. Frontiers in molecular neuroscience, 12, 143.
Brunoni, A. R., Carracedo, A., Amigo, O. M., Pellicer, A. L., Talib, L., Carvalho, A. F., ... & Cappi, C. (2019). Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial. Brazilian Journal of Psychiatry, 42, 128-135.
Cacabelos, R., & Torrellas, C. (2015). Pharmacogenomics of antidepressants. J. Psychiatr. Depress Anxiety, 1(001), 1-42.
Cascorbi, I., & Schwab, M. (2016). Epigenetics in drug response. Clinical Pharmacology & Therapeutics, 99(5), 468-470.
Fabbri, C., & Serretti, A. (2016). Pharmacogenetics of the efficacy and side effects of antidepressant drugs. Genetic influences on response to drug treatment for major psychiatric disorders, 39-54.
FDA. The FDA warns against the use of many genetic tests with unapproved claims to predict patient response to specific medications: FDA Safety Communication. Available at: https://www.fda.gov/medical-devices/safety-communications/fda-warns-against-use-many-genetic-tests-unapproved-claims-predict-patient-response-specific 2019
He, Q., Shen, Z., Ren, L., Wang, X., Qian, M., Zhu, J., & Shen, X. (2020). The association of catechol-O-methyltransferase (COMT) rs4680 polymorphisms and generalized anxiety disorder in the Chinese Han population. International Journal of Clinical and Experimental Pathology, 13(7), 1712.
Helton, S. G., & Lohoff, F. W. (2015). Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders. Pharmacogenomics, 16(5), 541-553.
Hicks, J. K., Bishop, J. R., Sangkuhl, K., Müller, D. J., Ji, Y., Leckband, S. G., ... & Gaedigk, A. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clinical Pharmacology & Therapeutics, 98(2), 127-134.
Jones, D. N., & Raghanti, M. A. (2021). The role of monoamine oxidase enzymes in the pathophysiology of neurological disorders. Journal of Chemical Neuroanatomy, 114, 101957.
Kang, H. J., Kim, K. T., Yoo, K. H., Park, Y., Kim, J. W., Kim, S. W., ... & Kim, J. M. (2020). Genetic markers for later remission in response to early improvement of antidepressants. International Journal of Molecular Sciences, 21(14), 4884.
Kuhn, D. M., & Hasegawa, H. (2020). Tryptophan hydroxylase and serotonin synthesis regulation. In Handbook of Behavioral Neuroscience (Vol. 31, pp. 239-256). Elsevier.
Kulikova, E. A., & Kulikov, A. V. (2019). Tryptophan hydroxylase 2 as a therapeutic target for psychiatric disorders: Focus on animal models. Expert Opinion on Therapeutic Targets, 23(8), 655-667.
Lauschke, V. M., Zhou, Y., & Ingelman-Sundberg, M. (2019). Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. Pharmacology & therapeutics, 197, 122-152.
Lin, E., & Lane, H. Y. (2015). Genome-wide association studies in pharmacogenomics of antidepressants. Pharmacogenomics, 16(5), 555-566.
Park, C., Rosenblat, J. D., Brietzke, E., Pan, Z., Lee, Y., Cao, B., ... & McIntyre, R. S. (2019). Stress, epigenetics and depression: a systematic review. Neuroscience & Biobehavioral Reviews, 102, 139-152.
Pigott, H. E. (2015). The STAR* D trial: It is time to reexamine the clinical beliefs that guide the treatment of major depression. The Canadian Journal of Psychiatry, 60(1), 9-13.
Pinna, M., Manchia, M., Pisanu, C., Pinna, F., Paribello, P., Carta, A., ... & Carpiniello, B. (2021). Protocol for a pharmacogenetic study of antidepressants: characterization of drug-metabolizing profiles of cytochromes CYP2D6 and CYP2C19 in a Sardinian population of patients with major depressive disorder. Psychiatric Genetics, 31(5), 186-193.
Probst-Schendzielorz, K., Scholl, C., Efimkina, O., Ersfeld, E., Viviani, R., Serretti, A., ... & Stingl, J. (2015). CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study. Pharmacogenomics, 16(7), 689-701.
RASHMI, S., SANGILIMUTHU, A. Y., & KUMAR, V. (2020). An evaluation of serotonergic genes polymorphism in the antidepressant response of major depressive disorder patients treated with escitalopram and venlafaxine. International Journal of Pharmaceutical Research (09752366).
Samardzic, J., Svob Strac, D., & van den Anker, J. N. (2017). The benefit and future of pharmacogenetics. Total Intravenous Anesthesia and Target Controlled Infusions: A Comprehensive Global Anthology, 697-711.
Shalimova, A., Babasieva, V., Chubarev, V. N., Tarasov, V. V., Schiöth, H. B., & Mwinyi, J. (2021). Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics. Pharmacogenomics, (0).
Shetty, P. (2019). Pharmacogenomics and its future implications in treatment-resistant depression. Ind. J. Priv. Psychiatry, 13, 71-76.
Singh, D. B. (2020). The impact of pharmacogenomics in personalized medicine. Current Applications of Pharmaceutical Biotechnology, 369-394.
Srivastava, K., Ochuba, O., Sandhu, J. K., Alkayyali, T., Ruo, S. W., Waqar, A., ... & Poudel, S. (2021). Effect of catechol-O-methyltransferase genotype polymorphism on neurological and psychiatric disorders: progressing towards personalized medicine. Cureus, 13(9).
Tao, S., Chattun, M. R., Yan, R., Geng, J., Zhu, R., Shao, J., ... & Yao, Z. (2018). TPH-2 gene polymorphism in major depressive disorder patients with early-wakening symptom. Frontiers in neuroscience, 12, 423425.
Tuscher, J. J., & Day, J. J. (2019). Multigenerational epigenetic inheritance: One step forward, two generations back. Neurobiology of Disease, 132, 104591.
Van Schaik, R. H., Müller, D. J., Serretti, A., & Ingelman-Sundberg, M. (2020). Pharmacogenetics in psychiatry: an update on clinical usability. Frontiers in Pharmacology, 11, 575540.
Van Westrhenen, R., Aitchison, K. J., Ingelman-Sundberg, M., & Jukić, M. M. (2020). Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going?. Frontiers in Psychiatry, 11, 479382.
Willner, P., Bergman, J., & Vanderschuren, L. (2019). The behavioural pharmacology of stress-related disorders. Behavioural Pharmacology, 30(2 and 3), 101-103.
Wyska, E. (2019). Pharmacokinetic considerations for current state-of-the-art antidepressants. Expert opinion on drug metabolism & toxicology, 15(10), 831-847.
Xin, J., Yuan, M., Peng, Y., & Wang, J. (2020). Analysis of the deleterious single-nucleotide polymorphisms associated with antidepressant efficacy in major depressive disorder. Frontiers in Psychiatry, 11, 151.
Yeung, A. W. K., Georgieva, M. G., Atanasov, A. G., & Tzvetkov, N. T. (2019). Monoamine oxidases (MAOs) as privileged molecular targets in neuroscience: research literature analysis. Frontiers in molecular neuroscience, 12, 143.
Article Sidebar
Published
Dec 14, 2022
Article Details
How to Cite
Abdullah Abdu Naship Sharahili 6 Nawaf Marzuq Aleufi 7 , Assaf Habyan Alshammari8 , Madloul Araak Alshammari9 , Amal Nawaf Alshammari 10, M. M. S. S. A. A. A. F. A. R. M. M. A. 3 F. M. O. A.-S. 4 S. F. S. A. 5. (2022). Understanding the Pharmacogenomics of Anti-depressant Response: Insights from Pharmacy, Laboratory Science, Nursing and Psychology. Journal of Population Therapeutics and Clinical Pharmacology, 29(04), 1399-1408. https://doi.org/10.53555/jptcp.v29i04.5901
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Abdullah Abdu Naship Sharahili 6 Nawaf Marzuq Aleufi 7 , Assaf Habyan Alshammari8 , Madloul Araak Alshammari9 , Amal Nawaf Alshammari 10, M. M. S. S. A. A. A. F. A. R. M. M. A. 3 F. M. O. A.-S. 4 S. F. S. A. 5. (2022). Understanding the Pharmacogenomics of Anti-depressant Response: Insights from Pharmacy, Laboratory Science, Nursing and Psychology. Journal of Population Therapeutics and Clinical Pharmacology, 29(04), 1399-1408. https://doi.org/10.53555/jptcp.v29i04.5901